Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: A systematic review

European Psychiatry

Volumn 27, Issue 5, 2012, Pages 343-349

  Caisley, H ^a,b,c   Muller U ^a,c,d  

^a Adult Attention Deficit Hyperactivity Disorder (ADHD) Research Clinic   (United Kingdom)

^b PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^c CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adherence; Adults; Amphetamine; Attention deficit hyperactivity disorder; Methylphenidate; Pro re nata

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; DEXAMPHETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; PEMOLINE; PSYCHOSTIMULANT AGENT;

ATTENTION DEFICIT DISORDER; COGNITIVE THERAPY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; HEALTH BELIEF; HUMAN; MEDICAL RECORD REVIEW; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SHORT SURVEY; STUDY DESIGN; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE;

EID: 84862558077     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2012.01.002     Document Type: Short Survey

References (46)

1. Adler L., Nierenberg A. Review of medication adherence in children and adults with ADHD. Postgrad Med 2010, 122(1):184-191.
2. American Psychiatric Association (APA) Diagnostic and Statistical Manual of Mental Disorders (4th edition text revision) 2000, APA, Washington (DC).
3. Barkley R. Global issues related to the impact of untreated attention deficit/hyperactivity disorder from childhood to young adulthood. Postgrad Med 2008, 120(3):48-59.
4. Biederman J., Faraone S.V. Attention deficit hyperactivity disorder. Lancet 2005, 366:237-248.
5. Biederman J., Faraone S.V., Spencer T.J., Mick E., Monuteaux M.C., Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006, 67(4):524-540.
6. ® methylphenidate. Prog Neuro-psychopharmacol Biol Psychiatry 2011, 35(2):554-560.
7. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) Canadian ADHD Practice Guidelines, Third Edition 2011, CADDRA, Toronto, ON.
8. Capone N, Mc Donnel T. Medication persistence among agents used to treat attention deficit/hyperactivity disorder, diabetes and elevated serum cholesterol. American Psychiatric Association (APA) annual meeting. Toronto; APA; 2006.
9. Christensen L., Sasané R., Hodgkins P., Harley C., Tetali S. Pharmacological treatment patterns among patients with attention deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 2010, 26(4):977-989.
10. Corman C.A., Hallowell E.M. Positively ADD: real success stories to inspire your dreams 2006, Walker and company, New York.
11. Dodson W.W. Pharmacotherapy of adult ADHD. J Clin Psychol 2005, 61(5):589-606.
12. Gillick V. West Norfolk and Wisbech Area Health Authority 1985, 3 All ER 402.
13. Halmøy A., Fasmer O.B., Gillberg C., Haavik J. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. J Atten Disord 2009, 13(2):175-187.
14. Juniper E.F., Guyatt G.H., Ferrie P.J., King D.R. Sodium cromoglycate eye drops: regular versus " as needed" use in the treatment of seasonal allergic conjunctivitis. J Allergy Clin Immunology 1994, 94(1):36-43.
15. Kessler R.C., Lane M., Stang P.E., Van Brunt D.L. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med 2009, 39:137-147.
16. Kooij S.J.J., Bejerot S., Blackwell A., Caci H., Casas-Brugué M., Carpentier P.J., et al. European consensus statement on diagnosis and treatment of adult ADHD: the European network adult ADHD. BMC Psychiatry 2010, 10:67.
17. Larriviere D., Williams M.A., Rizzo M., Bonnie R.J., AAN ethics, law, humanities committee Responding to requests from adult patients for neuroenhancements. Guidance of the ethics, law and humanities committee. Neurology 2009, 73:1406-1412.
18. McBurnett K., Starr H.L. OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder. Expert Opin Pharmacother 2011, 12(2):315-324.
19. Murphy A., Barkley K.A. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry 1996, 37(6):393-401.
20. National Institute for Health and Clinical Excellence (NICE). Attention deficit hyperactivity disorder - diagnosis and management of ADHD in children, young people and adults. NICE Clinical Guideline 72. The British Psychological Society and The Royal College of Psychiatrists, UK; 2008.
21. Newcorn J.H., Weiss M., Stein M. The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. CNS Spectr 2007, 12(8 Suppl. 12):1-16.
22. Nieuwkerk P.T., de Boer van der Kolk I.M., Prins J.M., Locadia M., Sprangers M.A. Self-reported adherence is more predictive of virological treatment response among patients with a lower tendency towards socially desirable responding. Antivir Ther 2010, 15(6):913-916.
23. Nosé M., Barbui C., Gray B., Tansella M. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003, 183:197-206.
24. Nutt D.J., Fone K., Asherson P., Bramble D., Hill P., Matthews K., et al. British Association for Psychopharmacology. Evidence-based guidelines for management of attention deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2006, 21:10-41.
25. Nyström I., Trygg T., Woxler P., Ahlner J., Kronstrand R. Quantitation of R-(-)- and S-(+)- amphetamine in hair and blood by gas chromatography-mass spectrometry: an application to compliance monitoring in adult attention deficit hyperactivity disorder treatment. J Anal Toxicol 2006, 29:682-688.
26. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
27. Perwien A.R., Hall J., Swensen A., Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention deficit/hyperactivity disorder. J Manag Care Pharm 2004, 10(2):122-129.
28. Polanczyk G., Rohde L.A. Epidemiology of attention deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 2007, 20(4):386-392.
29. Ramos-Quiroga J.A., Bosch R., Castells X., Valero S., Nogueira M., Gómez N., et al. Effect of switching drug formulations from immediate release to extended release OROS methylphenidate. A chart review of Spanish adults with attention deficit hyperactivity disorder. CNS Drugs 2008, 22(7):603-611.
30. Retz W., Rösler M. The relation of ADHD and violent aggression: what can we learn from epidemiological and genetic studies?. Int J Law Psychiatry 2009, 32:235-243.
31. Rösler M., Casas M., Konofal E., Buitelaar J. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry 2010, 11:684-698.
32. Sabaté E. Adherence to long-term therapies: evidence for action 2003, World Health Organisation, Geneva, Available from URL: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf.
33. Sachdev P.S., Troller J.N. How high a dose of stimulant medication in adult attention deficit hyperactivity disorder?. Aust N Z J Psychiatry 2000, 34:645-650.
34. Safren S.A., Duran P., Yovel I., Perlman C.A., Sprich S. Medication adherence in psychopharmacologically treated adults with ADHD. J Atten Disord 2007, 10(3):257-260.
35. Secnik K., Swensen A., Lage M.J. Comorbidities and costs of adult patients diagnosed with attention deficit hyperactivity disorder. Pharmacoeconomics 2005, 23(1):93-102.
36. Seixas M, Weiss M, Müller U. Systematic review of national and international guidelines on attention deficit hyperactivity disorder. J Psychopharmacol 2011, , [Epub ahead of print]. doi:10.1177/0269881111412095.
37. Simon V., Czobor P., Bálint S., Mészáros A., Bitter I. Prevalence and correlates of adult attention deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009, 194:204-211.
38. Swanson J. Compliance with stimulants for attention deficit/hyperactivity disorder. Issues and approaches for improvement. CNS Drugs 2003, 17(2):117-131.
39. Torgersen T., Gjervan B., Rasmussen K. Treatment of adult ADHD: is current knowledge useful to clinicians?. Neuropsychiatr Dis Treat 2008, 4(1):177-186.
40. Upadhyaya H. Managing attention deficit/hyperactivity disorder in the presence of substance use disorder. J Clin Psychiatry 2007, 68(Suppl. 11):23-30.
41. Waxmonsky J.G. Non-stimulant therapies for attention deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol 2005, 6(5):262-276.
42. Weisler R.H., Biederman J., Spencer T.J., Wilens T.E., Faraone S.V., Chrisman A.K., et al. Mixed amphetamine salts extended release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006, 11(8):625-639.
43. Westra H.A., Stewart S.H., Conrad B.E. Naturalistic manner of benzodiazepine use and cognitive behavioural therapy outcome in panic disorder with agoraphobia. J Anxiety Disord 2002, 16:233-246.
44. Wheeler R. Gillick or Fraser? A plea for consistency over competence in children Gillick and Fraser are not interchangeable. BMJ 2006, 332:807.
45. Wilens T.E. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry 2004, 65(Suppl. 3):38-45.
46. Wilens T.E. The nature of the relationship between attention deficit/hyperactivity disorder and substance use. J Clin Psychiatry 2007, 68(Suppl. 11):4-8.